<?xml version="1.0" encoding="UTF-8"?><xml><records><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Kazanis, Konstantinos</style></author><author><style face="normal" font="default" size="100%">Dalamaga, Maria</style></author><author><style face="normal" font="default" size="100%">Nounopoulos, Charalampos</style></author><author><style face="normal" font="default" size="100%">Manolis, Antonios S</style></author><author><style face="normal" font="default" size="100%">Sakellaris, Nikolaos</style></author><author><style face="normal" font="default" size="100%">Jullien, Gerard</style></author><author><style face="normal" font="default" size="100%">Dionyssiou-Asteriou, Amalia</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Ischemia modified albumin, high-sensitivity c-reactive protein and natriuretic peptide in patients with coronary atherosclerosis.</style></title><secondary-title><style face="normal" font="default" size="100%">Clin Chim Acta</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Clin. Chim. Acta</style></alt-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Adult</style></keyword><keyword><style  face="normal" font="default" size="100%">Aged</style></keyword><keyword><style  face="normal" font="default" size="100%">Aged, 80 and over</style></keyword><keyword><style  face="normal" font="default" size="100%">Antioxidants</style></keyword><keyword><style  face="normal" font="default" size="100%">Biomarkers</style></keyword><keyword><style  face="normal" font="default" size="100%">C-Reactive Protein</style></keyword><keyword><style  face="normal" font="default" size="100%">Case-Control Studies</style></keyword><keyword><style  face="normal" font="default" size="100%">Coronary Angiography</style></keyword><keyword><style  face="normal" font="default" size="100%">Coronary artery disease</style></keyword><keyword><style  face="normal" font="default" size="100%">Female</style></keyword><keyword><style  face="normal" font="default" size="100%">Humans</style></keyword><keyword><style  face="normal" font="default" size="100%">Male</style></keyword><keyword><style  face="normal" font="default" size="100%">Middle Aged</style></keyword><keyword><style  face="normal" font="default" size="100%">Natriuretic Peptides</style></keyword><keyword><style  face="normal" font="default" size="100%">Necrosis</style></keyword><keyword><style  face="normal" font="default" size="100%">Serum albumin</style></keyword><keyword><style  face="normal" font="default" size="100%">Troponin T</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2009</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2009 Oct</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">408</style></volume><pages><style face="normal" font="default" size="100%">65-9</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">BACKGROUND: Ischemia modified albumin (IMA), is a new biomarker of oxidative processes involved with coronary artery disease (CAD). We determined serum IMA, high-sensitivity C-reactive protein (hsCRP), and natriuretic peptide (NT-proBNP), and evaluated their correlation with severity of coronary atherosclerosis in patients undergoing coronary angiography (CA). Cardiac troponin T (cTnT), CK-MB mass, albumin and Total Antioxidant Status (TAS) were also evaluated.

METHODS: The study included 114 patients (88 men and 30 women) aged 43-80 years with documented CAD without evidence of acute coronary syndrome undergoing CA and 163 controls (131 men and 32 women) similarly aged.

RESULTS: IMA, hsCRP and NT-proBNP were higher (p&lt;0.001 and p=0.008 for NT-proBNP) while TAS was lower (p&lt;0.001) in patients than in controls. IMA and TAS were negatively correlated in all subjects (p&lt;0.01). Among patients, there was no correlation between IMA and the number of diseased vessels. For CAD diagnosis the best cut-off point for IMA was 101.5 KU/L with a sensitivity and a specificity of 87.7% and a negative predictive value of 83.3%. IMA was associated with an increased risk for CAD (OR=1.23, 95% CI: 1.16-1.31; p&lt;0.001).

CONCLUSIONS: IMA determination may provide earlier information of CAD presence before hsCRP or NT-proBNP elevation, contributing to early assessment of overall patient risk.</style></abstract><issue><style face="normal" font="default" size="100%">1-2</style></issue><custom1><style face="normal" font="default" size="100%">http://www.ncbi.nlm.nih.gov/pubmed/19625006?dopt=Abstract</style></custom1></record></records></xml>